GlobalData on MSN19d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...
Medical News Today12d
Nucala administration
Nucala (mepolizumab) is a brand-name subcutaneous injection that comes in different forms. Depending on which form you’re prescribed, you or your doctor will administer the injection.
Medscape3d
New ACG Guideline on EoE Reflects Over a Decade of Advances in Diagnosis and Management
The guidelines support use of PPIs, dietary therapy, and biologics for EoE, and stress the importance of addressing both the ...
pharmaphorum1d
GSK says Nucala hits the target in new COPD trial
The headline result from the MATINEE trial of IL-5 inhibitor Nucala (mepolizumab) in adults with COPD was a statistically significant reduction in the annualised rate of moderate or severe ...
pharmaphorum1d
FDA says no to AZ's Fasenra for nasal polyp indication
Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab) was approved to treat CRSwNP in 2019, and was joined on the US market by GSK's IL-5 inhibitor Nucala (mepolizumab) last year.
Pharmaceutical Technology4d
Mepolizumab by GSK for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
Mepolizumab is under clinical development by GSK and currently in Phase III for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase III drugs for Chronic Obstructive Pulmonary ...
thorax.bmj28d
Mepolizumab in corticosteroid-resistant eosinophilic asthma
Two recent well-designed randomised controlled trials have investigated the safety and efficacy of selected IL5 inhibition with mepolizumab (monoclonal antibody against IL5) in a ...
Future Market Insights7d
Global Nasal Allergy Treatment Market to Reach USD 13.3 Billion by 2033 at a CAGR of 6.7% | Data by Future Market Insights, Inc.
According to Future Market Insights, the global nasal allergy treatment market is poised for substantial growth, with its valuation expected to double from USD 6.6 billion in 2022 to USD 13.3 billion ...
Pharmaceutical Technology19d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
Credit: MAXSHOT.PL / Shutterstock. The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat ...
thorax.bmj28d
P15 Cost effectiveness of mepolizumab for severe eosinophilic asthma from the uk perspective
Mepolizumab is licensed for use in patients with severe eosinophilic asthma. As reimbursement authorities expect evidence of health economic benefits, this study aimed to estimate the cost-utility of ...
BMJ29d
Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities
The anti-IL-5 antibody mepolizumab at the dose of 300 mg/4 weeks has proven to be safe and effective in EGPA. While relapsing patients—who often experience recurrent respiratory manifestations—benefit ...